Completed PHASE2 INTERVENTIONAL 1-arm NCT00975975

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Sponsor: Indiana University School of Medicine

Conditions Acute Lymphocytic Leukemia Acute Myelogenous Leukemia Anemia, Aplastic Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Hemoglobinuria, Paroxysmal Hodgkin's Disease Multiple Myeloma Myelodysplasia Myelofibrosis Non-Hodgkin's Lymphoma

Interventions Basiliximab

Updated 5 times since 2017 Last updated: Jan 28, 2016 Started: Sep 30, 2009 Primary completion: Oct 31, 2012 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Lymphocytic Leukemia and Acute Myelogenous Leukemia and is currently completed. Indiana University School of Medicine leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University School of Medicine

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States